Unfavorable‐risk cytogenetic abnormalities and TP53 mutations were correlated with favorable clinical response and robust (but incomplete) mutation clearance in AML and MDS treated by decitabine.537. This evidence concerns the gene TP53 and acute myeloid leukemia.